Počet záznamů: 1
Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin
- 1.
SYSNO ASEP 0543521 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin Tvůrce(i) Tvrdý, V. (CZ)
Pourová, J. (CZ)
Jirkovský, E. (CZ)
Křen, Vladimír (MBU-M) RID, ORCID
Valentová, Kateřina (MBU-M) RID, ORCID
Mladěnka, P. (CZ)Zdroj.dok. Medicinal Research Reviews. - : Wiley - ISSN 0198-6325
Roč. 41, č. 4 (2021), s. 2195-2246Poč.str. 52 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova absorption ; excretion ; interactions ; metabolism ; silybin Vědní obor RIV FR - Farmakologie a lékárnická chemie Obor OECD Pharmacology and pharmacy CEP GA18-00121S GA ČR - Grantová agentura ČR Způsob publikování Omezený přístup Institucionální podpora MBU-M - RVO:61388971 UT WOS 000618017000001 EID SCOPUS 85101444463 DOI 10.1002/med.21791 Anotace Silymarin is an extract from the seeds (fruits) of Silybum marianum that contains flavonolignans and flavonoids. Although it is frequently used as a hepatoprotective agent, its application remains somewhat debatable, in particular, due to the low oral bioavailability of flavonolignans. Moreover, there are claims of its potential interactions with concomitantly used drugs. This review aims at a systematic summary and critical assessment of known information on the pharmacokinetics of particular silymarin flavonolignans. There are two known major reasons for poor systemic oral bioavailability of flavonolignans: (1) rapid conjugation in intestinal cells or the liver and (2) efflux of parent flavonolignans or formed conjugates back to the lumen of the gastrointestinal tract by intestinal cells and rapid excretion by the liver into the bile. The metabolism of phase I appears to play a minor role, in contrast to extensive conjugation and indeed the unconjugated flavonolignans reach low plasma levels after common doses. Only about 1%-5% of the administered dose is eliminated by the kidneys. Many in vitro studies tested the inhibitory potential of silymarin and its components toward different enzymes and transporters involved in the absorption, metabolism, and excretion of xenobiotics. In most cases, effective concentrations are too high to be relevant under real biological conditions. Most human studies showed no silymarin-drug interactions explainable by these suggested interferences. More interactions were found in animal studies, likely due to the much higher doses administered. Pracoviště Mikrobiologický ústav Kontakt Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Rok sběru 2022 Elektronická adresa https://onlinelibrary.wiley.com/doi/abs/10.1002/med.21791
Počet záznamů: 1